ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Eisai acquires rights to lemborexant from Purdue Pharma
May 05, 2019Eisai has bought the rights to investigational drug lemborexant from Purdue Pharma, ending a global development and commercialisation alliance signed in 2015. -
FDA accepts NDA for Lemborexant to treat Insomnia
March 12, 2019The NDA submission was based on data from the clinical development program including two pivotal Phase 3 studies of lemborexant - SUNRISE 1 (Study 304) and SUNRISE 2 (Study 303). -
New Drug Application for Insomnia Disorder Treatment Lemborexant Submitted in the United States
January 24, 2019Eisai Co., Ltd. (CEO: Haruo Naito, “Eisai”) and Purdue Pharma L.P. (President and CEO: Craig Landau, MD, “Purdue Pharma”) today announced that ... -
Eisai and Purdue Pharma seek US approval for lemborexant to treat insomnia
January 17, 2019Eisai and its partner Purdue Pharma have submitted new drug application to the US Food and Drug Administration (FDA) seeking approval for lemborexant to treat insomnia, a sleep disorder..... -
NDA for Lemborexant Submitted in the United States
January 16, 2019Eisai and Purdue Pharma announced a new drug application has been submitted to the U.S. Food and Drug Administration (FDA) for lemborexant ....
Pharma Sources Insight January 2025
